Pernod Ricard (RI.PA): Buying the World's #2 Spirits Company at Book Value While the Family Holds #

23 May 2026 | Price: EUR 64.76 | Position: 4 shares @ EUR 73.24 (T1) | Total cost: EUR 292.96 | P&L: -11.6%

The set-up in one paragraph #

Pernod Ricard is the world's second-largest premium spirits company — Jameson, Absolut, Chivas Regal, Martell, Ballantine's — trading at 1.05x book value and a 7.3% dividend yield. The stock is down 63% from its EUR 218 peak (April 2023), crushed by China's anti-dumping duties on EU brandy (cognac sales collapsed 39% by volume in 2025), US spirits destocking (H1 FY26: -15% organic), and a 15% US tariff on EU spirits with Trump threatening 200%. The founding Ricard family controls 28.7% of the company and spent ~EUR 6M buying shares at EUR 87-89 in late 2025 — they're now sitting on a ~27% paper loss and haven't sold a single share. We bought 4 shares on March 6 at EUR 73.24. The stock has since dropped another 11.6% to EUR 64.76. The investment question is whether this is a cyclical trough in a structurally durable business — or whether the headwinds (China cognac, GLP-1 weight-loss drugs, US tariffs, cannabis substitution) are permanent impairments that justify permanently lower multiples. Let's walk through both sides honestly.

Part 1: The Bull Case #

1. The valuation is genuinely distressed #

At EUR 64.76, Pernod Ricard trades at:

This is not a "slightly cheap" consumer staple. This is a company priced for permanent earnings impairment. At 11.6x trailing earnings, the market is implying ~1.5% long-term growth from Graham's formula (V = EPS × (8.5 + 2g)). Pernod's own medium-term guidance targets 3-6% organic growth. The gap between what's priced in and what management is targeting is where the return lives.

2. Q3 FY26 showed the first stabilization #

The April 16 trading update was the first positive data point in four quarters:

• Q3 organic sales: +0.1% — flat, but the first non-negative quarter after -5.9% in H1
• Volume returned to +4% growth — people are still drinking; pricing/mix was the drag
• China improved to -7% (from -28% in H1) — the cognac collapse is decelerating
• India +11% — the EM growth engine is firing

Management cut full-year guidance to -3% to -4% organic decline, citing Middle East travel retail disruption. That's disappointing, but at 11x earnings, "the decline is slowing" is enough. The stock doesn't need a boom — it needs the market to stop pricing in a permanent decline.

3. The founding family is the conviction anchor #

The Ricard family — Alexandre Ricard (CEO) and Société Paul Ricard (family vehicle) — spent ~EUR 6M buying shares at EUR 87-89 in October-November 2025. They now sit on a ~27% paper loss. They have not sold a single share.

This matters for three reasons:

1. They know the business better than any analyst. The family has run this company for 50 years. They've seen cycles. They bought aggressively at EUR 87-89 because they believe the value is there.
2. They're aligned. With 28.7% ownership and 22% of voting rights, they're not traders — they're permanent capital. If they're buying and holding through a 63% drawdown, they see something the market doesn't.
3. The negative signal would be catastrophic. If the family started selling now, it would be the single most bearish signal possible. They haven't. Per [shr-002], systematic insider buying by the controlling family is the strongest bullish signal in the framework.

Goldman Sachs crossed the 5% ownership threshold in April 2026 via off-market accumulation — institutional smart money is also buying the dip.

4. The moat is physical, not just a brand #

Pernod holds EUR 8.4 billion of aged spirits inventory — scotch, cognac, and Irish whiskey aging in barrels, with 87% of work-in-progress being ageing inventory. You cannot replicate 25-year-old Chivas Regal or Martell XO. This is a real physical moat, not a marketing story: new entrants cannot create aged inventory, and the inventory itself appreciates with time.

Gross margins have held at 59-60% through the entire downturn — pricing power is intact. If the brands were truly impaired, gross margins would be collapsing.

5. India and EM — the thesis beyond China #

While China dominates the narrative, Pernod is the #1 spirits company in emerging markets at 45% share. India grew +11% in Q3. 17 million new adults enter the legal drinking age in India every year. The EM growth story — rising middle class, premiumization, brand loyalty — is structurally durable in a way that China's cognac cycle is not.

The company's medium-term framework (FY27-29) targets 3-6% organic growth with margin expansion. A EUR 1 billion efficiency program is running through FY29. Structural costs have already been cut 10%.

6. The Brown-Forman overhang is gone #

The March 26 news that Pernod was in talks to acquire Brown-Forman (Jack Daniel's) for ~USD 11B sent the stock to EUR 59.94 — a 52-week low. The market correctly saw a transformative, highly leveraged deal on an already-stretched balance sheet as value-destructive. On April 28, the talks were officially terminated (mutual decision on valuation, structure, and domicile). Sazerac emerged with a competing USD 15B bid for BF.B.

The balance sheet overhang is resolved. Net debt/EBITDA stands at ~3.1x — below the 3.8x reported at H1, and well below the 5.0x EXIT trigger. The EUR 1.2B annual dividend is under pressure from the 84% payout ratio, but EUR 10.3B of net debt at 3.1x leverage is manageable for an investment-grade consumer company.

Part 2: The Bear Case #

1. The dividend isn't covered by free cash flow #

This is the single most important bear point, and it's not in the price. FY25 free cash flow was ~EUR 1.1 billion. The annual dividend costs ~EUR 1.2 billion. That's an 84% payout ratio on earnings and over 100% of FCF. The company is borrowing to pay the dividend.

The thesis lists "FCF below EUR 800M for two consecutive fiscal years" as an EXIT trigger. At the current run rate, FCF is already below the dividend — the only question is whether it crosses EUR 800M. H1 FY26 FCF was EUR 482M, which annualizes to ~EUR 960M. That's above EUR 800M but below the EUR 1.2B dividend. The dividend coverage gap is real, and FY26 full-year results (August 2026) will be the acid test.

If the dividend gets cut below EUR 4.00 (the RE-SCORE trigger), two things happen: (1) the 7.3% yield that attracts income investors disappears, potentially triggering another leg down, and (2) the thesis must be re-scored on all five qualitative factors.

2. EV-based valuation tells a different story #

When you look at P/E (11.6x), the stock looks cheap. When you look at enterprise value:

The EUR 10.3B of net debt — mostly from the 2008 acquisition of Vin & Sprit (Absolut Vodka) — means the equity is a leveraged bet on the recovery of spirits earnings. At 24x EV/FCF, this is not a "dirt cheap" stock. It's fairly valued on an enterprise basis, with the equity appearing cheap only because of the leverage.

The German Value Investor (YouTube review, May 2026) made exactly this point: the P/E hides the debt load. The Graham screen catches this — RI.PA fails the "long-term debt not exceeding working capital" filter — but the thesis underweights it.

3. China cognac may be structural, not cyclical #

The China research (March 2026) identified a critical shift: whisky has overtaken brandy as China's #1 imported spirits category. Cognac imports collapsed 39% by volume and 42% by value in 2025. Whisky imports surged 23%.

This is not just anti-dumping duties. Chinese consumer preferences are shifting — and in a way that directly hurts Pernod's anchor brand in China (Martell cognac). Martell was down 17% organic in H1 FY26, and excluding China, Martell grew ~20%. The China problem is entirely a Martell problem — and it may not reverse even if the duties are lifted.

Euromonitor forecasts cognac as the only spirits category declining in both value and volume through 2026. Remy Cointreau's Q3 cognac recovery (+3.2%) and guidance lift provide some hope, but Remy's China exposure is structured differently (higher-end, more resilient customer base).

4. The 200% tariff threat is existential if implemented #

The US is ~20% of Pernod's revenue. The existing 15% tariff costs ~EUR 80M/year (7-8% of operating profit). Trump's threatened 200% tariff on EU wine and spirits — retaliation for the EU's 50% tariff on US whiskey — would be catastrophic. At 200%, EU spirits become uncompetitive in the US market overnight.

Is it likely? Probably not — it would destroy American jobs in distribution, hospitality, and retail that depend on EU spirits. But "unlikely" is not zero, and the market is pricing some probability of this outcome. The tariff uncertainty also freezes retailer ordering patterns — even if the 200% never materializes, the threat depresses volumes.

5. GLP-1 drugs and cannabis — structural demand headwinds #

Two structural trends that didn't exist in Pernod's historical 20x P/E multiple:

• GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro): 12% of US adults now use them (up from 3% in 2021). Studies show they reduce alcohol consumption by 36-68%. This isn't a cyclical headwind — it's a permanent reduction in the addressable market for alcohol.
• Cannabis legalization: Heavy cannabis users drink ~33% less alcohol. Legalization is expanding in the US, Germany, and other key markets. Cannabis is a direct substitute for the "relaxation" occasions that spirits dominate.

These don't kill the thesis — EM growth (India +11%, 17M new legal-age drinkers/year) likely more than offsets developed-market volume decline. But they make the historical 18-20x P/E a less reliable anchor for "fair value." The multiple compression might be partly structural.

6. No insider buying in 2026 #

The family bought EUR 6M worth at EUR 87-89 in October-November 2025. Since then: zero insider purchases, zero insider sales. Six months of silence. The price is now EUR 64-65. If the family believed this was a screaming bargain, why aren't they buying more?

Possible explanations: (1) they're restricted by blackout periods around results, (2) they've deployed their personal capital and are waiting, (3) the Q3 stabilization isn't convincing enough yet. But the silence is notable. The bear read is: even the family thinks the headwinds are uncertain enough to wait.

7. Analyst consensus 2029 EPS still below 2025 #

Sell-side consensus for FY2029 EPS is ~EUR 6.66 — below FY2025's EUR 7.26. The market isn't pricing a recovery to peak earnings (EUR 8.81) within the next 4 years. Our thesis assumes mean-reversion to normalized earnings of EUR 6.45-8.81 — consensus says the "new normal" is lower.

From the Q3 FY26 guidance cut: "organic net sales -3% to -4% for FY26, with Middle East travel retail disruption as an additional headwind." Every time the company provides guidance, the recovery gets pushed further out.

8. Rising short interest #

OTC short interest in Pernod (PDRDF) has risen 75% since October 2025, with 39.2 days to cover. The shorts are not trapped — they're winning. Per [shr-023], this is "high short interest = informed bearish conviction," not squeeze fuel. The shorts have done their work and are staying short.

9. Competitive context: sector-wide, not RI-specific #

The counter to the "buy the dip" argument is that the entire sector is down: Diageo -20%, Remy Cointreau -20%, Brown-Forman -20%, Pernod -16% (on the 3-month view). This is a sector repricing, not a company-specific overreaction. Buying Pernod means betting that the sector is mispriced, not just one stock.

The Diageo comparison is instructive: DEO trades at 19.9x P/E with 3.9% yield. Pernod trades at 11.6x with 7.3% yield. The discount is real, but so is the risk differential — Pernod has higher China cognac exposure, weaker FCF coverage, and a family-controlled governance structure that limits activist pressure.

Part 3: Where We Stand #

The original thesis, revisited #

The RED→AMBER tracker (per shr-034) #

Net: two flags improved (China, M&A), one resolved (M&A), one new risk added (GLP-1/cannabis), US tariff still the wildcard.

Graham IV sensitivity at EUR 64.76 #

Using V = EPS × (8.5 + 2g) with trailing EPS EUR 5.58:

At EUR 64.76, the break-even growth rate is ~1.3%. If you believe Pernod can compound earnings at more than 1.3% long-term, the stock is undervalued. The question is whether the "E" in that formula is stable — and that's where the bear case lands.

Part 4: Conclusion — Hold T1, Wait for August #

This is a harder call than Arkema. Both are cyclical-inflection bets at trough multiples, but the difference is balance-sheet quality. Arkema generates EUR 643M FCF on EUR 4.7B market cap (13.7% FCF yield) with a 35% payout ratio. Pernod generates ~EUR 1B FCF on EUR 16.3B market cap (6% FCF yield) with an 84% payout ratio and EUR 10.3B of debt. You're paying more for less financial flexibility.

The bull case is real: Q3 showed stabilization, the family isn't selling, EM growth is durable, the moat is physical, and at 11.6x P/E the market is pricing near-zero growth for a business that demonstrably grows over cycles. The bear case is also real: dividend coverage is thin, EV/FCF is not cheap, China cognac may be structurally impaired, GLP-1/cannabis are permanent demand headwinds, and a 200% US tariff — however unlikely — would be catastrophic.

The right response is to hold T1 and wait.

We bought 4 shares at EUR 73.24. They're underwater by 11.6%. None of the four EXIT triggers have been hit: the family isn't selling, net debt/EBITDA is 3.1x (below 5.0x), FCF isn't below EUR 800M for two consecutive years, and the dividend hasn't been cut. The thesis is stressed but not broken. Selling now would be capitulating at the point of maximum pessimism — exactly what Graham warns against.

T2 (EUR ~220, ~3 shares) should wait for FY26 full-year results in August 2026. Four data points need confirmation:

1. China trajectory: Q3 at -7% was encouraging. FY26 results will show whether Q4 sustained that improvement. One quarter of deceleration is not a trend.
2. Gross margin: Sales-only Q3 didn't disclose it. Last reading was 59.3% (H1). Need to see no further erosion below 57%.
3. FCF and dividend: The critical question is whether FY26 FCF covers the dividend. Management may pre-announce a dividend decision. If FCF is below EUR 1B, the cut risk becomes material.
4. Family activity: Six months of silence since the last purchases. If the family resumes buying at EUR 60-65, deploy T2 immediately per [shr-002]. If they start selling, exit T1 too.

The early override conditions from the execution log remain in force: family buying at current levels → deploy T2; 200% tariff de-escalation → reassess; price below EUR 58 (below all analyst targets) → reassess risk/reward.

If I had to make a call today: Pernod Ricard at EUR 64.76 is probably a good investment over a 3-5 year horizon, but it's not a great one. The upside to EUR 110-130 (70-100%) exists if the cycle normalizes, but the path is uncertain and the balance sheet adds risk that pure P/E compression doesn't capture. It's in that uncomfortable middle ground: too cheap to sell, not clean enough to buy more. The August results are the next real decision point. Until then, collect the 7.3% dividend and watch.

Position: 4 shares RI.PA @ EUR 73.24. T2 pending FY26 results (Aug 2026). Not investment advice. I am long RI.PA.